{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigènes CD11c : Questions médicales les plus fréquentes",
"headline": "Antigènes CD11c : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigènes CD11c : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigènes CD11c"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Intégrine alphaX bêta2",
"url": "https://questionsmedicales.fr/mesh/D016167",
"about": {
"@type": "MedicalCondition",
"name": "Intégrine alphaX bêta2",
"code": {
"@type": "MedicalCode",
"code": "D016167",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.350.275"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigènes CD11c",
"alternateName": "CD11c Antigen",
"code": {
"@type": "MedicalCode",
"code": "D039521",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lifei Hou",
"url": "https://questionsmedicales.fr/author/Lifei%20Hou",
"affiliation": {
"@type": "Organization",
"name": "Cardiac Anesthesia Division, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA."
}
},
{
"@type": "Person",
"name": "Koichi Yuki",
"url": "https://questionsmedicales.fr/author/Koichi%20Yuki",
"affiliation": {
"@type": "Organization",
"name": "Cardiac Anesthesia Division, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA."
}
},
{
"@type": "Person",
"name": "Wakiro Sato",
"url": "https://questionsmedicales.fr/author/Wakiro%20Sato",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Immunology (E.A., W.S., A.K., T. Yamamura), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo; Department of Neurology and Neurological Sciences (E.A., T. Yokota), Tokyo Medical and Dental University, Bunkyo; Department of Radiology (Y.K., N.S.); and Department of Neurology (Y.L., T.O.), National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Youwei Lin",
"url": "https://questionsmedicales.fr/author/Youwei%20Lin",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Immunology (E.A., W.S., A.K., T. Yamamura), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo; Department of Neurology and Neurological Sciences (E.A., T. Yokota), Tokyo Medical and Dental University, Bunkyo; Department of Radiology (Y.K., N.S.); and Department of Neurology (Y.L., T.O.), National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Tomoko Okamoto",
"url": "https://questionsmedicales.fr/author/Tomoko%20Okamoto",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Immunology (E.A., W.S., A.K., T. Yamamura), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo; Department of Neurology and Neurological Sciences (E.A., T. Yokota), Tokyo Medical and Dental University, Bunkyo; Department of Radiology (Y.K., N.S.); and Department of Neurology (Y.L., T.O.), National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer.",
"datePublished": "2022-07-13",
"url": "https://questionsmedicales.fr/article/35834142",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12064-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Use of Wearable Activity Monitors to Measure Upper Limb Physical Activity After Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy.",
"datePublished": "2023-07-28",
"url": "https://questionsmedicales.fr/article/37507555",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-023-13966-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection.",
"datePublished": "2023-04-22",
"url": "https://questionsmedicales.fr/article/37086333",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11255-023-03595-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic performance of Node Reporting and Data System (Node-RADS) for assessing mesorectal lymph node in rectal cancer by CT.",
"datePublished": "2024-06-11",
"url": "https://questionsmedicales.fr/article/38862951",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-024-12487-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non-small Cell Lung Cancer.",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/35676168",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cllc.2022.05.006"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes de surface",
"item": "https://questionsmedicales.fr/mesh/D000954"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'adhérence cellulaire",
"item": "https://questionsmedicales.fr/mesh/D015815"
},
{
"@type": "ListItem",
"position": 6,
"name": "Intégrine alphaX bêta2",
"item": "https://questionsmedicales.fr/mesh/D016167"
},
{
"@type": "ListItem",
"position": 7,
"name": "Antigènes CD11c",
"item": "https://questionsmedicales.fr/mesh/D039521"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigènes CD11c - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigènes CD11c",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigènes CD11c",
"description": "Comment diagnostiquer une expression anormale de CD11c ?\nQuels tests sont utilisés pour détecter les antigènes CD11c ?\nLes antigènes CD11c sont-ils spécifiques à certaines maladies ?\nQuelle est l'importance des antigènes CD11c dans le diagnostic ?\nPeut-on mesurer les niveaux de CD11c dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigènes CD11c",
"description": "Quels symptômes sont associés à une surexpression de CD11c ?\nLa présence de CD11c est-elle liée à des symptômes spécifiques ?\nLes antigènes CD11c sont-ils liés à des symptômes neurologiques ?\nComment les symptômes varient-ils selon les niveaux de CD11c ?\nLes symptômes d'une maladie liée à CD11c sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigènes CD11c",
"description": "Peut-on prévenir les maladies liées à CD11c ?\nY a-t-il des vaccins liés aux antigènes CD11c ?\nComment le dépistage précoce aide-t-il à prévenir les complications ?\nLes habitudes alimentaires influencent-elles CD11c ?\nLe stress a-t-il un impact sur CD11c ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigènes CD11c",
"description": "Quels traitements ciblent les antigènes CD11c ?\nLes traitements sont-ils efficaces contre les maladies liées à CD11c ?\nY a-t-il des effets secondaires aux traitements ciblant CD11c ?\nComment les traitements sont-ils adaptés aux niveaux de CD11c ?\nLes traitements sont-ils disponibles pour tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigènes CD11c",
"description": "Quelles complications peuvent survenir avec CD11c élevé ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées à CD11c ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigènes CD11c",
"description": "Quels sont les facteurs de risque pour CD11c élevé ?\nL'âge influence-t-il les niveaux de CD11c ?\nLe mode de vie affecte-t-il les niveaux de CD11c ?\nLe stress est-il un facteur de risque pour CD11c ?\nLes infections antérieures influencent-elles CD11c ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD11c ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse se fait par cytométrie en flux pour évaluer l'expression de CD11c sur les cellules."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les antigènes CD11c ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunologiques comme l'immunofluorescence et la cytométrie en flux sont utilisés."
}
},
{
"@type": "Question",
"name": "Les antigènes CD11c sont-ils spécifiques à certaines maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur expression est souvent associée à des maladies comme la leucémie ou le lupus."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance des antigènes CD11c dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à identifier certains sous-types de cellules immunitaires et à diagnostiquer des pathologies."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer les niveaux de CD11c dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de CD11c peuvent être mesurés dans le sang par des techniques de laboratoire."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une surexpression de CD11c ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des manifestations immunitaires comme des infections récurrentes."
}
},
{
"@type": "Question",
"name": "La présence de CD11c est-elle liée à des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surexpression peut être liée à des symptômes d'auto-immunité ou d'inflammation."
}
},
{
"@type": "Question",
"name": "Les antigènes CD11c sont-ils liés à des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent un lien potentiel entre CD11c et des troubles neurologiques dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les niveaux de CD11c ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés peuvent entraîner des symptômes plus graves d'inflammation ou d'auto-immunité."
}
},
{
"@type": "Question",
"name": "Les symptômes d'une maladie liée à CD11c sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la maladie sous-jacente; certains symptômes peuvent être réversibles avec traitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées à CD11c ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives comme un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins liés aux antigènes CD11c ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques ciblant les antigènes CD11c."
}
},
{
"@type": "Question",
"name": "Comment le dépistage précoce aide-t-il à prévenir les complications ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce permet d'identifier les anomalies et d'initier un traitement rapide."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD11c ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut moduler la réponse immunitaire et l'expression de CD11c."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur CD11c ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la fonction immunitaire et l'expression de CD11c."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les antigènes CD11c ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies immunomodulatrices et des anticorps monoclonaux peuvent cibler CD11c."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre les maladies liées à CD11c ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent réduire l'inflammation et améliorer les symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ciblant CD11c ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des réactions allergiques ou des infections peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils adaptés aux niveaux de CD11c ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont ajustés en fonction des niveaux de CD11c et de la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils disponibles pour tous les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'accès aux traitements peut varier selon les pays et les systèmes de santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CD11c élevé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections graves ou des maladies auto-immunes peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à CD11c ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications chroniques existent, surtout en cas de maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour CD11c élevé ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux de maladies auto-immunes et des infections."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de CD11c ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut influencer l'expression de CD11c et la réponse immunitaire globale."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les niveaux de CD11c ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les niveaux de CD11c."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour CD11c ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter l'expression de CD11c et affecter la santé immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections antérieures influencent-elles CD11c ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections antérieures peuvent moduler l'expression de CD11c et la réponse immunitaire."
}
}
]
}
]
}
When a positive sentinel lymph node (SLN) is identified after neoadjuvant chemotherapy (NAC), completion axillary lymph node dissection (cALND) is generally recommended. We sought to evaluate the rate...
We identified all patients at our hospital between 2006 and 2021 with a positive SLN (> 0.2 mm) following NAC who underwent cALND. Rates of positive non-SLN (NSLN) on cALND were compared by nodal stat...
Overall, 229 cases (177 cN+, 52 cN0 prior to NAC) with positive SLN(s) after NAC underwent cALND. Additional NSLN involvement was found in 129/229 (56.3%) patients, including 24/52 (46.2%) cN0 and 105...
Rates of nodal positivity on cALND in the setting of positive SLN after NAC are high, supporting the current standard of routine cALND. In cN+ disease, NSLN positivity varies by tumor biology, multice...
We suspect that morbidity from both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) has been inadequately evaluated to date. Current methodologies are subjective and suscep...
A prospective, single center, observational study was conducted from February 2020 to May 2022. Consecutive patients undergoing breast and/or reconstructive surgery and axillary surgeries were identif...
Patients who underwent ALND experienced significantly worse PA compared with those who underwent SLNB in week 2 (median 66.4% versus 72.7%, p = 0.015). Subgroup analysis revealed significantly lower P...
Compared with SLNB, ALND results in a lower PA level in week 2. The findings also indicate that SLNB has a protracted effect on PA levels, which extend to 2 weeks postoperatively. Monitoring recovery ...
To assess the negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection....
A retrospective analysis of patients who underwent robotic-assisted radical prostatectomy with pelvic lymph node dissection and had a preoperative negative PSMA PET scan for metastasis was performed. ...
The overall negative predictive value of PSMA PET scan was 71.6%. Further sub-classification according to risk stratification demonstrated a NPV of 58.02%, 92.7% and 90% for high, intermediate and low...
Pelvic lymph node dissection cannot be excluded based on a negative preop PSMA PET/CT scan....
To compare the diagnostic performance of the Node-RADS scoring system and lymph node (LN) size in preoperative LN assessment for rectal cancer (RC), and to investigate whether the selection of size as...
Preoperative CT data of 146 RC patients treated with radical resection surgery were retrospectively analyzed. The Node-RADS score and short-axis diameter of size-prioritized LNs and the morphology-pri...
Node-RADS score showed significant correlation with pN stage, LNM number and LNR (Node-RADS of size-prioritized LN: r = 0.600, 0.592, and 0.606; Node-RADS of morphology-prioritized LN: r = 0.547, 0.53...
The Node-RADS scoring system outperforms the short-axis diameter in predicting lymph node metastasis in RC. Size-prioritized LN demonstrates superior predictive efficacy compared to morphology-priorit...
Past studies have shown mixed results of postoperative radiation (PORT) for pN2 NSCLC patients. We hypothesize that PORT can improve overall survival (OS) in pN2 NSCLC patients with high lymph node ra...
The National Cancer Database was queried for non-metastatic pN2 NSCLC patients with R0 surgery and adjuvant chemotherapy from 2004 to 2016. Cox models were used to assess the impact of PORT and LNR on...
Among 4,050 patients, 1,728 (42.7%) had PORT. There was increased use of IMRT in the more recent period (53.8% in 2010-2016 vs 24.0% in 2004-2009). PORT was associated with better OS in the overall co...
PORT was associated with better survival for pN2 NSCLC patients after R0 resection, adequate LND with high LNR, after accounting for multiple confounders. Among the whole cohort, most of the OS benefi...
In select colorectal cancer patients with metastatic retroperitoneal lymph node disease, surgical resection can be performed. We discuss our robotic technique....
We aimed to assess the prognostic impact of tumor- and patient-related parameters in patients with stage I-III small intestinal neuroendocrine tumors (SI-NETs), who underwent locoregional resective su...
The population in Western countries differs significantly from that in Eastern countries, and the prevalence of lateral pelvic lymph node (LPLN) involvement in Western populations remains largely unkn...
This retrospective single center study was designed to elaborate the LPLNP score, which was further tested on a prospective cohort of patients. Clinical and MRI factors associated with LPLN involvemen...
In the retrospective series, 120 patients underwent lateral pelvic lymph node dissection. After stepwise logistic regression, five parameters were ultimately included in the LPLNP score. When tested o...
The LPLNP score was developed based on the largest group of Western patients with locally advanced rectal cancer. This scoring system demonstrated high sensitivity and specificity during validation on...
Lymph node metastases often occur in advanced gastric cancer, with some patients presenting with metastases in the para-aortic lymph nodes. There are persistent Controversies about the benefit of para...
To retrospectively analyze the clinical data of 86 gastric cancer patients (40 in the D2 + PAND group and 46 in the D2 group) who attended the abdominal surgery department of Zhejiang Cancer Hospital ...
In the D2 + PAND group (40 cases), the average number of lymph nodes cleared per case was 4.3 in group 16 (16a2, 16b1), and the postoperative pathology confirmed lymph node positivity in 16 cases, wit...
For patients with gastric cancer whose imaging suggests metastasis in the para-aortic lymph nodes, preoperative chemotherapy combined with PAND is an effective and safe treatment that may benefit pati...
Findings from randomized clinical trials have shown that survival in patients with sentinel lymph node (SLN)-negative breast cancer is noninferior with SLN biopsy (SLNB) alone versus further axillary ...
We included patients diagnosed with pathologically staged T1-2N0M0 breast cancer between 2000 and 2015 in surveillance, epidemiology, and end results 18-registry database. Patients were considered to ...
We included 309,430 patients (253,501 SLNB and 55,929 ALND). In the weighted cohort, ALND was associated with significantly lower OS (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.10-1.16) an...
We found statistically significant differences in OS and BCSS between SLNB and ALND, though the magnitude of these differences was small. Our findings further support that SLNB alone should be the sta...
